Molnupiravir
| Product Name | Molnupiravir |
|---|---|
| Alternate Names | Molnupiravir Impurities, Impurities of Molnupiravir |
| CAT No. | CS-N-04590 |
| CAS No. | 2349386-89-4 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 329.31 g/mol |
| Mol. For. | C₁₃H₁₉N₃O₇ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Molnupiravir |
| Canonical Smiles | CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)NO)O)O |
| InchIKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N |
| Inchl | InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1 |
| IUPAC | [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Molnupiravir is an antiviral medication that has been recently developed to treat COVID-19. It is a prodrug that is converted into its active form, which then interferes with viral replication by introducing errors in the genetic material of the virus. This mechanism of action makes it effective against a wide range of RNA viruses, including SARS-CoV-2.
Molnupiravir is administered orally and is currently undergoing clinical trials to evaluate its efficacy and safety. Preliminary results from these trials show promising results, with reduced hospitalization rates and faster recovery times in patients who received the medication.
Chemically, Molnupiravir is a nucleoside analog with a molecular formula of C13H19N3O7. It is structurally similar to the nucleosides present in RNA, which allows it to be incorporated into the viral genetic material during replication. Once incorporated, it causes mutations in the viral RNA, which results in non-functional viral particles.
The safety profile of Molnupiravir is still being evaluated, but early studies suggest that it is generally well-tolerated with few adverse effects. However, it should be used with caution in patients with liver or kidney dysfunction, as well as those who are pregnant or breastfeeding.
Overall, Molnupiravir shows promise as a potential treatment for COVID-19, and further studies are underway to determine its efficacy and safety in larger patient populations.
Get an Instant Quote
Related Compounds
Molnupiravir Impurity C | Beta-d-N4-hydroxycytidine | molnupiravir Imp H | Molnupiravir E isomer | Molnupiravir Impurity H | Molnupiravir Impurity A | Molnupiravir Impurity B | N-Butyl Molnupiravir | Molnupiravir α anomer | molnupiravir Imp J | Molnupiravir Impurity 4 | Molnupiravir Impurity E | Molnupiravir Enantiomer | Molnupiravir Acetyl Impurity |